Abzena Limited provides contract research, development, and manufacturing services for biologics and bioconjugates, supporting drug discovery, development, and GMP manufacturing from early research through to commercial production. The company delivers integrated drug design, development, and GMP manufacturing services for biologics, bioconjugates, and antibody-drug conjugates, covering the full lifecycle from discovery to commercial production. Services include antibody discovery, lead selection and optimization, developability assessments, and formulation development for therapeutic molecules such as peptides, proteins, monoclonal antibodies, and ADCs. The company develops synthetic routes for cytotoxins, payloads, linkers, and highly potent active pharmaceutical ingredients, and provides analytical method development and testing for bioconjugate formulation. Facilities support early discovery, design, development, and commercial manufacturing across mammalian, microbial, and bioconjugate modalities, with both predefined and tailored work packages available. The company serves pharmaceutical and biotechnology companies involved in the development and commercialization of biologic drugs, bioconjugates, and antibody drug conjugates, as well as clients seeking contract research, development, and manufacturing services for novel treatments. The company was founded in 2014 and is based in Cambridge, United Kingdom.